1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tasly Pharmaceutical Group Co., Ltd

Tasly Pharmaceutical Group Co., Ltd

600535.SS
Tasly Pharmaceutical Group Co., LtdCN flagShanghai Stock Exchange
14.43
CNY
+0.43
- -
21.56BMarket Cap
Tasly Pharmaceutical Group Co., Ltd
600535.SS
(Shanghai Stock Exchange)

Recent

price

14.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.39
4.53
6.44
7.66
8.67
8.82
9.23
10.64
11.88
12.52
9.04
5.29
5.88
5.83
5.69
5.52
5.63
Revenue per Share
0.33
0.42
0.59
0.76
0.94
0.99
0.78
0.91
1.02
0.66
0.75
1.57
-0.18
0.72
0.64
0.74
0.71
Basic EPS, GAAP
0.17
-0.2
-0.07
-0.32
-0.1
-0.27
0.42
-0.86
0.47
0.63
0.92
1.48
1.28
1.28
0.97
0.7
-0.41
Free Cash Flow per Basic Share
0.17
0.25
0.3
0.17
0.42
0.42
0.41
0.61
0.57
0.6
0.53
0.41
0.38
0.38
0.7
0.42
0.56
Dividend per Share
1.09
1.19
1.5
2.11
2.73
3.31
3.7
4.13
5.03
5.32
5.71
6.86
6.35
6.58
6.46
6.79
6.78
Book Value per Share
2.27
2.32
2.73
2.37
2.93
4.49
4.72
5.15
6.25
6.53
7.14
7.67
7.54
7.16
6.74
6.99
7.05
Tangible Book Value per Share
1,370
1,449
1,452
1,450
1,451
1,500
1,511
1,513
1,515
1,517
1,501
1,502
1,468
1,488
1,493
1,493
1,494
Basic Weighted Avg Shares
4,652
6,570
9,343
11,108
12,578
13,228
13,945
16,094
17,990
18,998
13,576
7,952
8,637
8,674
8,498
8,236
8,415
Sales/Revenue/Turnover
12.88
11.38
13.27
14.42
15.8
15.53
12.26
13.51
13.62
10.52
11.3
16.5
15.81
17.35
17.59
17.66
16.74
Operating Margin (%)
111
118
169
193
239
290
309
342
357
387
540
488
518
505
496
455
- -
Depreciation Expense
450
611
850
1,098
1,368
1,479
1,176
1,377
1,545
1,001
1,126
2,359
-264
1,071
956
1,105
1,068
Net Income, GAAP
17.31
18.56
17.24
17.77
16.31
15.14
18.52
19.25
18.61
24.62
25.2
11.6
- -
16.74
19.62
21.1
15.66
Effective Tax Rate (%)
9.68
9.3
9.1
9.88
10.88
11.18
8.44
8.55
8.59
5.27
8.29
29.66
-3.06
12.35
11.24
13.42
12.69
Profit Margin (%)
1,392
1,245
1,672
737
1,022
3,311
3,017
3,709
9,303
7,886
6,302
7,394
7,113
6,363
4,961
5,922
5,705
Working Capital
225
63
501
869
812
798
400
892
5,156
3,232
1,133
1,116
1,452
1,496
322
268
189
LT Debt
3,425
3,776
4,499
4,178
5,068
7,707
8,207
8,974
11,208
11,864
12,384
13,314
12,678
12,690
12,111
12,548
12,601
Total Equity
12.94
12.91
19.64
21.26
20.34
16.59
12.02
12.1
10.43
7.39
6.48
7.58
- -
8.22
8.18
8.19
7.94
Return on Invested Capital (%)
19.51
22.33
27.45
24.55
21.09
18.99
14.68
13.48
11.6
7.71
9.54
19.58
- -
9.71
9.04
10.11
9.36
Return on Capital (%)
32.91
37.96
43.51
41.89
38.96
33.13
22.27
23.23
22.27
12.76
13.52
24.98
-2.69
11.21
9.83
11.17
10.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,334
1,050
1,504
LT Borrowings
254
151
140
LT Finance Leases
68
52
50
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,494
1,494
1,494
Market Capitalization
21,603
22,572
23,379

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
7,311
7,369
8,169
Cash, Cash Equivalents & STI
3,518
2,930
4,227
Accounts Receivable, Net
780
971
1,140
Inventories
1,712
1,616
1,556
Total Current Liabilities
2,350
2,455
2,465
Payables & Accruals
- -
- -
- -
ST Debt
1,334
1,050
1,504
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.28%
0.37%
3.6%
Free Cash Flow
-64.68%
-0.99%
-28.02%
Net Income, GAAP
-51.61%
-100.44%
15.63%
Sales/Revenue/Turnover
-2.78%
-7.5%
-3.08%
Total Cash Common Dividend
4.84%
2.91%
-39.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,049
2,323
2,091
2,036
8,498
2025
2,055
2,233
1,926
- -
8,236
2026
2,165
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
- -
- -
- -
0.64
2025
0.21
- -
- -
- -
0.74
2026
0.25
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.7
2025
0.21
- -
- -
- -
0.42
2026
- -
- -
- -
- -
- -
Similar Companies
Molecule Holdings Inc. (MLCL.CN)
Kali, Inc. (KALY)
AcuCort AB (ACUC.ST)
Eisai Co., Ltd. (4523.T)
Indocan Resources Inc. (IDCN)
Grape King Bio Ltd (1707.TW)
Business
Tasly Pharmaceutical Group Co., Ltd (600535.SS) researches, develops, manufactures and sells traditional Chinese medicines, chemical preparations, biological products and health care items primarily in China and internationally. Founded in 1994 and headquartered in Tianjin, China, the company operates through segments including biopharmaceuticals, healthcare products and medical services, offering prescription drugs for cardiovascular and cerebrovascular conditions, hepato-biliary-pancreatic disorders, respiratory issues, diabetes, tumor immunity, gastrointestinal diseases, gynecology, rheumatism, neurology, pruritus and andrology; over-the-counter drugs; herbal medicines; chemical raw materials; pharmaceutical substances and APIs; herbal extracts; concentrated herbal granules; health supplements; and medical devices. Its flagship products feature flagship offerings like Danhong injection alongside a broad portfolio integrating traditional Chinese medicine with modern techniques, targeting domestic markets that account for the majority of revenue alongside growing international presence in regions including the United States. Recent developments include China Resources Sanjiu Medical's acquisition of a 28% stake valued at 6.212 billion yuan to expand in traditional Chinese medicine, alongside approvals for clinical trials of the stem cell therapy NR-20201 for acute ischemic stroke, strategic partnerships such as with Arfive for health product distribution in Henan, and investments in ventures like Hygieia Biotechnology.